NY-ESTÉE-LAUDER
The Estée Lauder Companies Inc. (NYSE: EL) (“ELC” or “the Company”) today announced that Akhil Shrivastava has been appointed Executive Vice President and Chief Financial Officer, succeeding Tracey T. Travis, whose intention to retire was announced on July 11, 2024. Akhil will report to William P. Lauder, Executive Chairman, and Fabrizio Freda, President and Chief Executive Officer, consistent with the reporting structure for Tracey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723453390/en/
The Estée Lauder Companies Names Akhil Shrivastava as Executive Vice President and Chief Financial Officer, Effective November 1, 2024 (Photo: Business Wire)
Akhil will assume his new role effective November 1, 2024. Tracey will remain at the Company until her retirement on June 30, 2025 to support a seamless transition.
“With over 25 years of extensive financial and leadership experience, Akhil is an exceptional and capable leader whose financial and strategic expertise and insights have been important in supporting the Company over the past several years, and he will be instrumental in driving forward our strategic direction and decisions,” said Fabrizio Freda. “I look forward to partnering with Akhil as we continue to rebuild stronger, more sustainable profitability and sales growth acceleration across the business.”
In his new role as Chief Financial Officer, Akhil will be responsible for the Company’s Global Finance, Accounting, Tax, Treasury, Investor Relations and New Business Development organizations. He will lead ELC’s Global Finance & Strategy (F&S) organization and will continue to cultivate and strengthen the tremendously talented Finance & Strategy Team, continuing to imbue agility and consumer-focus across the organization to drive sustainable value creation, governance, and strategic business objectives and priorities for the long-term.
Since joining ELC in 2015, Akhil has held several senior finance roles within the Company. He was recently named ELC’s Senior Vice President, Corporate Controller, a role that oversees Corporate Accounting and Financial Planning & Analysis, the International and Online Finance organizations, Pricing and Value Chain Finance, serving on both the Finance & Strategy Leadership Team and Executive Leadership Team. He also oversees the Operational Excellence pillar as part of the Profit Recovery and Growth Plan focused on driving strong inventory, cash, and cost improvements for the Company. Prior to his current role, he was Senior Vice President, Treasurer, where he was responsible for core Treasury functions, the Enterprise Risk Program, Real Estate, and oversight of the Company’s retirement funds.
Akhil will serve as a member of several of ELC’s senior management leadership groups including the Executive Leadership Team, Investment Development Committee, Fiduciary Investment Committee, and Corporate Risk Management Committee. In some cases, his membership will continue, and, in others, he will be a new member.
“Akhil has demonstrated his capabilities as a transformational, visionary, and collaborative leader who combines finance and strategy with an appreciation for the creativity within our business and our brands with consumers at the heart,” said William P. Lauder. “He also has a keen ability to cultivate high-performing teams and organizations and will continue to strengthen the tremendously talented Finance & Strategy organization, which will be instrumental in continuing to drive our strategic business objectives and priorities for the long-term.”
Akhil first joined ELC in 2015 as Vice President, Global Finance & Strategy for the Estée Lauder brand and was then appointed to the role of Senior Vice President, Global Finance & Strategy for Jane Hertzmark Hudis’ Brand Cluster in January 2019, where he provided strategic leadership and financial guidance while maximizing business and transformational opportunities across the brand cluster. Specifically, he helped allocate resources to support and promote the best growth opportunities from a consumer, sub-category, geography, and channel perspective.
He has also served as a valued member of many key enterprise initiatives at the Company, providing strategic financial direction for projects which include transforming ELC’s planning processes and capabilities to support the end-to-end business from consumer demand to delivery.
“With its leading portfolio of iconic brands, extensive global reach, and impressively talented people, I am honored to lead the Global Finance team,” said Akhil Shrivastava. “I look forward to helping to advance the Company’s multiple engines of growth to rebuild stronger, more sustainable profitability and support sales growth acceleration across brands, product categories, and regions while evolving the business for the future.”
Before joining The Estée Lauder Companies, Akhil spent eighteen years at Procter & Gamble, where he served in several finance and leadership roles across Asia, North America, and the global businesses, including Finance Director for Gillette, North America.
Akhil is a graduate of Engineering College in Rewa, India and has a Master’s Degree in Finance and Control from Delhi University.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include the various quotations related to rebuilding profitability and sales growth and the future of the finance and strategy function. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s profit recovery and growth plan and those described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2023. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723453390/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
